Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits. The post Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry appeared first on Investor's Business Daily.
CryptoAlerta — análise de criptomoedas e mercado em tempo real